Pharmaceuticals

Global Leqvio Market 2026–2030: Forecast Insights for Business Planning

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the leqvio market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Leqvio Market in 2030?

Historical growth was largely driven by the increasing occurrence of hyperlipidemia, alongside advancements in RNA interference technology, the expansion of cardiovascular specialty clinics, a heightened awareness of LDL cholesterol management, and improved injectable drug delivery systems.

Anticipated market expansion over the forecast period is propelled by the escalating uptake of innovative RNA therapeutics, a heightened emphasis on mitigating cardiovascular risks, the broader availability of therapies with extended dosing intervals, increased capital allocation for cardiometabolic investigations, and a rising requirement for sustainable lipid-reducing interventions.

Significant trends expected during the forecast period encompass the increasing integration of siRNA-based lipid-reducing treatments, an escalating desire for cardiovascular therapies offering prolonged effects, a concentrated effort on developing preventative cardiology approaches, the advancement of sophisticated RNA production techniques, and a stronger commitment to optimizing patient treatment adherence.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Drivers Are Influencing Production Trends In The Leqvio Market?

The increasing number of older adults is anticipated to propel the demand for leqvio in the future. This demographic segment typically includes individuals 65 years of age and older. Significant improvements in healthcare and medical advancements have substantially extended life expectancy, thereby fueling the expansion of the geriatric demographic. Leqvio is effective in reducing LDL cholesterol, simplifying medication regimens for elderly patients. Its extended duration of action diminishes cardiovascular hazards, thereby improving health results for older individuals. As an illustration, data from January 2024, provided by the Kenya-based nonprofit, the Population Reference Bureau, indicates that the count of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Concurrently, this demographic’s proportion of the total population is also forecast to increase from 17% to 23% over the identical timeframe. Consequently, the expanding geriatric populace is a key factor propelling the expansion of the leqvio market.

Which Segments Are Gaining Traction In The Leqvio Market?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Trends Are Reshaping The Dynamics Of The Leqvio Market?

Leading companies are active in the leqvio market, concentrating on creating sophisticated injectable prescription drugs, for example, through Label Expansion, to improve therapeutic reach and prompt intervention. Label Expansion signifies regulatory authorization from bodies like the FDA, enabling an already approved medication to be utilized for new indications, patient demographics, or clinical contexts beyond its initial authorization. As an illustration, in July 2023, Novartis AG, a pharmaceutical firm based in Switzerland, secured US Food and Drug Administration (FDA) approval for an updated label for Leqvio (inclisiran), permitting its application earlier for individuals having high LDL-C and a higher propensity for heart disease, alongside diet and statin therapy. Administered with two doses per year following two initial doses, it delivers up to a 52% LDL-C reduction and has demonstrated efficacy for patients struggling to achieve their LDL-C target even with statin therapy. This label update underscores strong safety and efficacy data, which was further supported by the VictORION clinical trial program.

Who Are The Major Companies Operating In The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Leqvio Market?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Leqvio Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795